HomeDiscover the ProgrammeScientific Programme

Scientific programme

The scientific programme is structured around basic science, translational medicine and clinical sessions, given by some of the world’s top specialists. It also includes oral presentations of the best abstracts, the announcement of ECCO Fellowships and Grants and summary presentations of new ECCO Guidelines.  The focus of all sessions is clinical practice founded on science, with practical messages to take home.
Scientific sessions are held from Thursday, February 15 to Saturday, February 17, 2018. The congress registration fee includes access to all scientific sessions.

Science improving patients' lives

  • Thursday, February 15, 2018
  • Friday, February 16, 2018
  • Saturday, February 17, 2018

  • Plenary hall

    11:00-12:00  
    		Industry sponsored satellite symposia 1a & 1b
    12:15-12:20   Welcome
    Rainer Schöfl, Linz, Austria
    12:20-12:30   Opening
    Julián Panés, Barcelona, Spain
    12:30-14:00
    		Scientific session 1: Exploring IBD over time
     Charlotte Hedin, Stockholm, Sweden
    Axel Dignass, Frankfurt/Main, Germany
      12:30-12:50   Can we diganose pre-symptomatic IBD?
     Joana Torres, Lisbon, Portugal
      12:50-13:00   OP001: Gut barrier dysfunction– a primary defect in twins with Crohn’s Disease predominantly caused by genetic predisposition
    Å. V Keita1, C.M. Lindqvist2, Å. Öst3, C. DL Magana1, I. Schoultz2, J. Halfvarson4
    1. Linköping University, Department Of Clinical And Experimental Medicine, Linköping, Sweden
    2. Örebro University, Department of Medical Sciences, Örebro, Sweden
    3. Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden
    4. Örebro University, Department of Gastroenterology, Örebro, Sweden
      13:00-13:20  
    		Targeting early disease - lessons from rheumatoid arthritis 
    Daniel Aletaha, Vienna, Austria
      13:20-13:30   OP002: Assessment of disease activity patterns during the first 10 years after diagnosis in a population-based Crohn’s Disease cohort shows a quiescent disease course for a substantial proportion of the population
    D. Wintjens1, 2, F. Bergey3, E. Saccenti4, S. Jeuring1, 2, M. Romberg-Camps5, L. Oostenbrug5, A. Masclee1, 2, D. Jonkers1, 2, V. Martins dos Santos3, 4, M. Pierik1, 2
    1. Maastricht University Medical Center +, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, Netherlands
    2. Maastricht University Medical Center +, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands
    3. LifeGlimmer GmbH, Berlin, Germany
    4. Wageningen University & Research, Laboratory of Systems and Synthetic Biology, Wageningen, Netherlands
    5. Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen/Heerlen, Netherlands
      13:30-13:40  OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics
    M. de Bruyn1, 2, V. Ballet3, S. Verstockt4, B. Verstockt1, 3, G. Van Assche1, 3, M. Ferrante1, 3, K. Machiels1, S. Vermeire1, 3
    1. Translational Research center for GastroIntestinal Disorders (TARGID), Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium
    2. Rega Institute for Medical Research, Microbiology and Immunology, Leuven, Belgium
    3. University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium
    4. Laboratory of Complex Genetics, Human Genetics, Leuven, Belgium
      13:40-14:00   Evolution of disease pathways over time in CD - early versus late disease 
    Gerhard Rogler, Zurich, Switzerland
    14:00-14:30 Coffee break 
    14:30-16:00 Scientific session 2: Novel treatment strategies
    Tim Raine, Cambridge, United Kingdom
    Matthieu Allez, Paris, France
      14:30-14:50 Combining new drugs with different mechanisms 
    Shomron Ben-Horin, Ramat Gan, Israel
      14:50-15:00 OP004: The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in Ulcerative Colitis
    H. Schmitt1, U. Billmeier1, J. Ulmschneider1, C. Admyre2, T. Knittel2, A. Zargari2, M.F. Neurath1, R. Atreya1
    1. Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany
    2. InDex Pharmaceuticals AB, Stockholm, Sweden
      15:00-15:20 Stem cell therapy for perianal CD - multidisciplinary management 
    Damián García-Olmo, Madrid, Spain
    Silvio Danese, Milan, Italy     
      15:20-15:30 OP005: Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s Disease patients
    A. Strik1, M. Löwenberg1, C. Ponsioen1, K. Gecse2, C. Buskens3, W. Bemelman3, G. D'Haens1
    1. Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands
    2. Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands
    3. Academic Medical Center (AMC), Department of Surgery, Amsterdam, Netherlands
      15:30-15:40 OP006: Apremilast for active Ulcerative Colitis: A phase 2, randomised, double-blind, placebo-controlled induction study 
    S. Danese1, M. Neurath2, A. Kopon3, S. Zakko4, T. Simmons5, R. Fogel6, J. Maccarone7, X. Zhan7, K. Usiskin7, D. Chitkara7
    1. Instituto Clinico Humanitas, Milan, Italy
    2. University Erlangen, Nurnberg, Germany
    3. Torunskie Centrum Gastrologiczne Gastromed, Torun, Poland
    4. Connecticut Clinical Research Foundation of Bristol Hospital, Bristol, United States
    5. West Gastroenterology Medical Group, Los Angeles, United States
    6. Clinical Research Institute of Michigan, Chesterfield, United States
    7. Celgene Corporation, Summit, United States
      15:40-16:00 Small molecules are back
    Laurent Peyrin-Biroulet, Vandeouvre-Les-Nancy, France
    16:00-17:20 Scientific session 3: Returning to a normal life with IBD
    Barry Hall, Dublin, Ireland
    Paula Ministro, Viseu, Portugal
      16:00-16:20 Sexual dysfunction in IBD patients
    Eugeni Domènech, Badalona, Spain
      16:20-16:40 How to prevent disability
    Jean-Frédéric Colombel, New York City, United States
      16:40-16:50 OP007: Detection of mucosal healing with a serum marker panel in adalimumab treated patients with Ulcerative Colitis
    M. de Bruyn1, 2, R. Ringold3, E. Martens2, M. Ferrante1, 4, G. Van Assche1, 4, G. Opdenakker2, A. Dukler3, S. Vermeire1, 4
    1. Translational Research center for GastroIntestinal Disorders (TARGID), Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium
    2. Rega Institute for Medical Research, Microbiology and Immunology, Leuven, Belgium
    3. Kepler Diagnostics, Inc., Simi Valley, United States
    4. University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium
      16:50-17:00 OP008: α4β7 integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages
    L. Schleier1, M. Wiendl1, M.-T. Binder1, R. Atreya1, A. Watson2, C. Neufert1, I. Atreya1, M.F. Neurath1, S. Zundler1
    1. University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany
    2. University of East Anglia, Norwich Medical School, Norwich, United Kingdom
      17:00-17:20 Patient perspective on treatment goals
    Corey Siegel, Lebanon, United States
    17:30-18:30 Digital oral presentations (Sessions 1-5)
    18:45-19:45
    		 Industry sponsored satellite symposia 2a, 2b, 2c

  • Plenary hall

    07:15-08:15 Industry sponsored satellite symposia 3a, 3b & 3c
    08:30-10:30 Scientific session 4: The future of IBD diagnosis and disease prediction
    Iris Dotan, Petah Tikva, Israel
    Jonas Halfvarson, Örebrö, Sweden
      08:30-08:50 ECCO-ESGAR Guidelines: Present and future of diagnostic techniques for IBD
    Jaap Stoker, Amsterdam, The Netherlands
    Christian Maaser, Lueneburg, Germany
      08:50-09:00 OP009: A combination of clinical, serological and genetic factors predicts complicated disease course in paediatric-onset Crohn’s disease: results from a population-based study.
    H. Sarter1, 2, G. Savoye3, D. Turck2, 4, F. Vasseur5, G. Marot6, 7, B. Pariente2, 8, S. Singh9, J.F. Colombel10, C. Gower-Rousseau1, 2, M. Fumery11
    1. Lille Hospital and University, Public Health, Epidemiology and Economic Health, Epimad registry, Regional house of clinical research, Lille, France
    2. Lille University, Lille Inflammation Research International Center LIRIC-UMR 995 Inserm, Lille, France
    3. Rouen Hospital and University, Gastroenterology Unit, Epimad registry, Rouen, France
    4. Lille University Jeanne de Flandre Children's Hospital and Faculty of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lille, France
    5. Lille University and Hospital, Biostatistics Unit, EA 2694, Lille, France
    6. Lille University and Hospital, EA 2694 - Santé publique : épidémiologie et qualité des soins, Lille, France
    7. Inria Lille Nord Europe, Modal, Lille, France
    8. Gastroenterology Unit, Epimad registry, Lille Hospital and University, Lille, France
    9. Prometheus Laboratories Inc., San Diego, United States
    10. Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States
    11. Amiens Hospital and University, Gastroenterology Unit, EPIMAD Registry, Amiens, France
      09:00-09:10 OP010: Shallow whole genome sequencing predicts the future cancer risk of low grade dysplastic lesions arising in Ulcerative Colitis
    I. Al Bakir1, 2, K. Curtius1, A.-M. Baker1, T.S.O. Clarke1, M. Moorghen3, M. Jansen4, M. Rodriguez-Justo4, S. Leedham5, T. Graham*1, A. Hart*2
    1. Queen Mary University of London, Barts Cancer Institute, London, United Kingdom
    2. St. Mark's Hospital, Inflammatory Bowel Disease Unit, Harrow, United Kingdom
    3. St. Mark's Hospital, Pathology Department, Harrow, United Kingdom
    4. University College London Hospital, Pathology Department, London, United Kingdom
    5. Henry Wellcome Building of Genomic Medicine, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
      09:10-09:20 OP011: Integration of whole exome sequencing and RNA sequencing of intestinal biopsies in Inflammatory Bowel Disease identifies inflammation dependent effects
    R. Barbieri1, W. Uniken Venema1, A. Vich Vila1, Y. Li1, L. Franke1, F. van Dijk1, N. De Klein1, M. Swertz1, S. Sanna1, M.D. Voskuil1, M. Rivas2, R. Xavier2, M. Daly2, G. Dijkstra1, E.A. Festen1, R.K. Weersma1
    1. UMCG, Groningen, Netherlands
    2. The Broad Institute of MIT and Harvard, Cambridge, United States
      09:20-09:40 Molecular endoscopy for IBD
    Raja Atreya, Erlangen, Germany
      09:40-09:50 OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn’s Disease patients 
    H. Schmitt1, U. Billmeier1, W. Dieterich1, T. Rath1, S. Sonnewald2, S. Reid2, S. Hirschmann1, K. Hildner1, M.J. Waldner1, J. Mudter3, A. Hartmann4, R. Grützmann5, C. Neufert1, T. Münster6, M.F. Neurath1, R. Atreya1
    1. Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany
    2. Friedrich-Alexander-University Erlangen-Nürnberg, Department of Biology, Erlangen, Germany
    3. Sana Kliniken Ostholstein, Eutin, Germany
    4. Friedrich-Alexander-University Erlangen-Nürnberg, Deparment of Pathology, Erlangen, Germany
    5. Friedrich-Alexander-University Erlangen-Nürnberg, Department of Surgery, Erlangen, Germany
    6. Friedrich-Alexander-University Erlangen-Nürnberg, Department of Anesthesiology, Erlangen, Germany
      09:50-10:00 OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's Disease
    A. Sazonovs1, N.A. Kennedy2, C. Bewshea2, L. Moutsianas1, G.J. Walker2, K. De Lange1, J. Goodhand2, C. Anderson1, J. Barrett1, PANTS Investigator Consortium, T. Ahmad2
    1. Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    2. University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom
      10:00-10:10 OP014:Analysis of 1792 gut metagenomes reveals microbial treatment targets for Inflammatory Bowel Disease and irritable bowel syndrome 
    A. Vich Vila1, F. Imhann1, V. Collij1, S.A. Jankipersadsing1, T. Gurry2, Z. Mujagic3, A. Kurilshikov1, M.J. Bonder1, J. Xiaofang2, E. Tigchelaar1, J. Dekens1, V. Peters1, M.D. Voskuil1, M.C. Visschedijk1, F. Eleonora A.M.1, G. Dijkstra1, A.A. Masclee3, M.H. Hofker1, R. Xavier4, E.J. Alm2, J. Fu1, C. Wijmenga1, D.M. Jonkers3, A. Zhernakova1, R.K. Weersma1
    1. University Medical Center Groningen, Groningen, Netherlands
    2. Massachusetts Institute of Technology, Boston, United States
    3. Maastricht University Medical Center (MUMC), Maastricht, Netherlands
    4. Broad Institute, Boston, United States
      10:10-10:30 Integration of "omics" and potential for clinical practice
    Claudio Fiocchi, Cleveland, United States
    10:30-11:00 Coffee Break
    11:00-12:30 Scientific session 5: New opportunities for IBD care and research
    Dominik Bettenworth, Münster, Germany
    James Lindsay, London, United Kingdom
      11:00-11:20 Remote monitoring
    Daniel Baumgart, Berlin, Germany
      11:20-11:40 Point of care tests
    Ann Gils, Leuven, Belgium
      11:40-12:00 Web-based registries 
    Pascal Juillerat, Bern, Switzerland
      12:00-12:10 OP015:Biomarker correlation with endoscopic outcomes in patients with Crohn’s Disease: Data from CALM
    W. Reinisch1, R. Panaccione2, P. Bossuyt3, F. Baert4, A. Armuzzi5, S. Travis6, S. Danese7, W.J. Sandborn8, G. D'Haens9, S. Berg10, J.-F. Maa11, J. Petersson11, E. Neimark11, A.M. Robinson11, J.-F. Colombel12
    1. Medical University of Vienna, Vienna, Austria
    2. University of Calgary, Calgary, Canada
    3. Imelda General Hospital, Bonheiden, Belgium
    4. AZ Delta Roeselare-Menen, Menen, Belgium
    5. Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy
    6. Oxford University Hospitals, Oxford, United Kingdom
    7. Istituto Clinico Humanitas, Milan, Italy
    8. University of California San Diego, La Jolla, United States
    9. Academic Medical Center, Amsterdam, Netherlands
    10. AbbVie AB, Solna, Sweden
    11. AbbVie Inc., North Chicago, United States
    12. Icahn School of Medicine at Mount Sinai, New York, United States
      12:10-12:30 Can the patient become an investigator?
    Germari Bianchi, Milan, Italy
    12:30-13:30 Break
    12:30-13:30 Guided poster session
    12:40-13:20
    		 Industry sponsored lunchtime satellite symposia LS1,LS2,LS3,LS4
    13:30-15:00 Scientific session 6: Best perioperative management of IBD
    Yves Panis, Clichy, France
    Walter Reinisch, Vienna, Austria
      13:30-13:50 Get your patient fit for surgery
    Paulo Kotze, Curitiba, Brazil; Calgary, Canada
    Peter Irving, London, United Kingdom
      13:50-14:00 OP016: Need for primary abdominal surgery, but not repeated surgery, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014
    D. Kalman1, C. Nordenvall2, A. Hallqvist Everhov3, J.F. Ludvigsson4, M.C. Sachs5, A. Ekbom6, O. Olén7, P. Myrelid1
    1. Division of surgery, Department of Clinical and Experimental Medicine, Faulty of Health Sciences, Linköping University and Department of Surgery, County Council of Östergötland, Linköping, Sweden
    2. Dept. of Molecular Medicine and Surgery, Karolinska Institutet; Center for Digestive Disease, Div. of Coloproctology, Karolinska University Hospital, Stockholm, Sweden
    3. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
    4. Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA, Stockholm, Sweden
    5. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    6. Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
    7. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of pediatric gastroenterology and nutrition, Sachs' Children and Youth Hospital, Stockholm, Sweden
      14:00-14:20 Enhanced postoperative recovery pathways
    Gionata Fiorino, Milan, Italy
    Antonino Spinelli, Milan, Italy
      14:20-14:30 OP017: Transanal minimally-invasive proctectomy with ileal pouch anal anastomosis (Ta-IPAA) in patients with Ulcerative Colitis: A cohort study from the TaTME international database
    G. Pellino1, 2, K. Sahnan2, 3, M. Penna3, 4, S. Adegbola2, 3, P. Chandrasinghe2, 3, 5, A. Spinelli6, 7, R. Hompes4, J. Warusavitarne2, 3, on behalf of the International TaTME Registry Collaborative.
    1. Università della Campania, Unit of Colorectal Surgery, Naples, Italy
    2. St Mark's Hospital, Fistula Research Unit, London, United Kingdom
    3. Imperial College, Department of Surgery and Cancer, London, United Kingdom
    4. Oxford University Hospital NHS Trust - Churchill Hospital, Department of Colorectal Surgery, Oxford, United Kingdom
    5. Faculty of Medicine, University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka
    6. Humanitas University, Colon and Rectal Surgery Unit, Department of General Surgery, Rozzano, Italy
    7. Humanitas University, Humanitas University, Department of Biomedical Sciences, Rozzano, Italy
      14:30-14:40 OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signaling
    C. Mascaraque1, S. Elangovan2, L. Petti1, A. Piontini2, C. Correale1, V. Arena3, B. Romano1, F. Ungaro2, V. Garlatti2, S. D'Alessio2, G. Fiorino1, A. Spinelli2, 4, S. Danese1, 2, S. Vetrano2
    1. Humanitas Research Institute, IBD Center Laboratory of Immunology in Gastroenterology, Rozzano, Italy
    2. Humanitas University, Department of Biomedical Sciences, Rozzano, Italy
    3. Catholic University of Rome, Institute of Pathology, Rome, Italy
    4. Humanitas Reseach Institute, Colon and Rectal Surgery, Rozzano, Italy
      14:40-15:00 Preventive strategy after resection surgery in CD
    Pierre Michetti, Lausanne, Switzerland
    15:00-15:30 Coffee break
    EITHER:
    15:30-16:10 Scientific session 7: ECCO Fellowships and Grants
    Gerhard Rogler, Zurich, Switzerland
    Dino Tarabar, Belgrade, Serbia
      15:30-15:37 Outcomes from the ECCO-IOIBD Fellowship 2016: The interleukin-1 pathway as a putative new target in paediatric Inflammatory Bowel Disease
    Sharon Veenbergen, Rotterdam, The Netherlands
      15:37-15:44 Outcomes from the ECCO-IOIBD Fellowship 2017: Precision medicine for IBD using advanced machine learning
    Aria Zand, Los Angeles, United States 
    15:44-15:50 Announcement of ECCO Fellowships & Grants 2018
      15:50-16:00 OP019: In Faecal Microbiota Transplantation (FMT) for Ulcerative Colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short chain fatty acid production are associated with remission (FOCUS study)
    S. Paramsothy1, 2, M. Kamm3, 4, S. Nielsen1, N. Deshpande1, J. Faith2, J. Clemente2, R. Paramsothy5, A. Walsh6, J. van den Bogaerde7, D. Samuel8, R. Leong8, S. Connor5, W. Ng5, E. Lin9, M. Wilkins1, J.-F. Colombel2, T. Borody9, H. Mitchell1, N. Kaakoush1
    1. University of New South Wales, Sydney, Australia
    2. Icahn School of Medicine at Mount Sinai, New York, United States
    3. St Vincent's Hospital, Melbourne, Australia
    4. University of Melbourne, Melbourne, Australia
    5. Liverpool Hospital, Sydney, Australia
    6. St Vincent's Hospital, Sydney, Australia
    7. Nambour General Hospital, Nambour, Australia
    8. Bankstown-Lidcombe Hospital, Sydney, Australia
    9. Centre for Digestive Diseases, Sydney, Australia
      16:00-16:10 OP020: The clinical determinants affect gut microbial profile of Inflammatory Bowel Disease patients
    P. Juillerat1, B. Yilmaz2, R. Wiest1, 2, G. Rogler3, A.J. Macpherson1
    1. Clinic for Visceral Surgery and Medicine, Gastroenterology, Bern, Switzerland
    2. University of Bern, Department of Biomedical Research, Bern, Switzerland
    3. University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland
    16:10-17:10 Scientific session 8: IBD Horizons
    Filip Baert, Roeselare, Belgium
    Gerassimos Mantzaris, Athens, Greece
      16:10-16:20 OP021: Autologous haematopoietic stem cell transplantation for Crohn’s Disease: A retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party
    C. Brierley1, C. Castilla-Llorente2, M. Labopin3, M. Badoglio3, M. Rovira4, E. Ricart5, D. Dierickx6, S. Vermeire7, P. Hasselblatt8, J. Finke9, F. Onida10, A. Cassinotti11, J. Satsangi12, M. Kazmi13, A. López-Sanromán14, D. Farge15, S. Travis16, C. Hawkey17, J. Snowden18
    1. Oxford University Hospitals, Department of Haematology, Oxford, United Kingdom
    2. Département d’Hématologie Gustave Roussy, Programme de transplantation des cellules souches, Villejuif, France
    3. Université Pierre et Marie Curie, Saint Antoine Hospital, EBMT Paris Study Office, Department of Haematology, Paris, France
    4. Hospital Clínic of Barcelona, Haematology Department, Barcelona, Spain
    5. Hospital Clínic of Barcelona, Gastroenterology Department, Barcelona, Spain
    6. University Hospitals Leuven, Department of Haematology, Leuven, Belgium
    7. University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium
    8. Medical Faculty and University Hospital Freiburg, Department of Medicine II, Freiburg, Germany
    9. University of Freiburg, Department of Gastroenterology, Freiburg, Germany
    10. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Haematology - BMT Centre, Milan, Spain
    11. Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy
    12. Western General Hospital, University of Edinburgh, Gastro-intestinal Unit, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom
    13. Guy's and St Thomas' NHS Foundation Trust and King's College Hospital, Department of Haematology, London, United Kingdom
    14. Ramon y Cajal Hospital, Gastroenterology and Hepatology Department, Madrid, Spain
    15. AP-HP Hôpital Saint-Louis, Centre de Référence des Maladies auto-immunes systémiques Rares d’Ile-de-France (site constitutif), Filière FAI2R, Internal Medicine, Autoimmune and Vascular Diseases Unit, UF 04, Paris, France
    16. Oxford University Hospitals, Translational Gastroenterology Unit, Oxford, United Kingdom
    17. Queen’s Medical Centre, Nottingham Digestive Diseases Centre, School of Clinical Sciences, Nottingham, United Kingdom
    18. Sheffield Teaching Hospitals NHS Foundation Trust, Department of Haematology, Sheffield, United Kingdom
      16:20-16:30 OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study
    S. Schreiber1, L. Peyrin-Biroulet2, B. Boland3, P.D. Higgins4, A. Armuzzi5, J. Terdiman6, W. Zhou7, G. Alperovich8, F. Cataldi7, S. Goteti7, A.P. Lacerda7
    1. University Hospital Schleswig-Holstein, Kiel, Germany
    2. University of Lorraine, Nancy, France
    3. University of California, San Diego, San Diego, United States
    4. University of Michigan, Ann Arbor, United States
    5. Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy
    6. University of California, San Francisco, Medical Center at Parnassus, San Francisco, United States
    7. AbbVie Inc., North Chicago, United States
    8. AbbVie Spain S.L.U., Madrid, Spain
      16:30-16:40 OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn's Disease (CD)
    S. Danese1, B. Feagan2, W. Sandborn3, J.-F. Colombel4, S. Vermeire5, S. Jones6, K. Brennan6, J. Bornstein7
    1. Humanities University, IBD Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
    2. University of Western Ontario, Robarts Clinical Trials, London, Ontario, Canada
    3. University of California, Inflammatory Bowel Disease Center, Division of Gastroenterology, San Diego, United States
    4. Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, NY, United States
    5. University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
    6. Europe Development Centre, Takeda R&D, London, United Kingdom
    7. Takeda Pharmaceuticals International Co., Cambridge, MA, United States
      16:40-16:50 OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II study
    G.R. D´Haens1, W. Reinisch2, S.D. Lee3, D. Tarabar4, E. Louis5, M. Kłopocka6, J. Klaus7, S. Schreiber8, D.I. Park9, X. Hébuterne10, F. Cataldi11, A. Banerjee12, K. Gorelick13, W.J. Sandborn14
    1. Academic Medical Centre, Amsterdam, Netherlands
    2. Medical University of Vienna, Vienna, Austria
    3. University of Washington, Seattle, United States
    4. Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia
    5. University Hospital CHU of Liège, Liège, Belgium
    6. Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
    7. Universitatsklinikum Ulm, Ulm, Germany
    8. University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany
    9. Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea
    10. Université de Nice Sophia Antipolis, Hôpital de l'Archet, Nice, France
    11. Shire, Lexington, United States
    12. Pfizer, Cambridge, United States
    13. Zymo Consulting Group, Newtown Square, United States
    14. University of California San Diego, La Jolla, United States
      16:50-17:00 OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor–antagonist therapy in Crohn’s Disease: A multicentre consortium propensity score–matched analysis
    M. Bohm1, S. V Sagi1, M. Fischer1, S. Kadire1, G. Tran1, M. Rahal1, S. Aniwan2, J. Meserve3, A. Weiss4, G. Kochhar5, P. Shashi5, D. Faleck6, A. Winters6, S. Chablaney6, J.L. Koliani-Pace7, B. Boland3, S. Singh3, R. Hirten6, E. Shmidt6, K. Lasch8, M. Luo8, D. Hudesman9, S. Chang9, D. Lukin4, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, S. Kane2, E.V. Loftus2, B.E. Sands6, W.J. Sandborn3, J.-F. Colombel6, B. Shen5, P.S. Dulai3
    1. Indiana University, Indianapolis, United States
    2. Mayo Clinic, Rochester, United States
    3. University of California - San Diego, La Jolla, United States
    4. Montefiore Medical Center, New York, United States
    5. Cleveland Clinic Foundation, Cleveland, United States
    6. Icahn School of Medicine at Mount Sinai, New York, United States
    7. Dartmouth-Hitchcock Medical Center, Lebanon, United States
    8. Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States
    9. New York University (NYU), New York, United States
    10. North Shore University Hospital, Manhasset, United States
    11. Lenox Hill Hospital, New York, United States
    12. University of Mississippi, Jackson, United States
      17:00-17:10 OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score–matched analysis
    D. Faleck1, P. Shashi2, J. Meserve3, M. Rahal4, S. Kadire4, G. Tran4, A. Weiss5, A. Winters1, S. Chablaney1, S. Aniwan6, J.L. Koliani-Pace7, G. Kochhar2, B. Boland3, S. Singh3, R. Hirten1, E. Shmidt1, K. Lasch8, M. Luo8, M. Bohm4, S. V Sagi4, M. Fischer4, D. Hudesman9, S. Chang9, D. Lukin5, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, B. Shen2, W.J. Sandborn3, B.E. Sands1, J.-F. Colombel1, S. Kane6, E.V. Loftus6, P.S. Dulai3
    1. Icahn School of Medicine at Mount Sinai, New York, United States
    2. Cleveland Clinic Foundation, Cleveland, United States
    3. University of California - San Diego, La Jolla, United States
    4. Indiana University, Indianapolis, United States
    5. Montefiore Medical Center, New York, United States
    6. Mayo Clinic, Rochester, United States
    7. Dartmouth-Hitchcock Medical Center, Lebanon, United States
    8. Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States
    9. New York University (NYU), New York, United States
    10. North Shore University Hospital, Manhasset, United States
    11. Lenox Hill Hospital, New York, United States
    12. University of Mississippi, Jackson, United States
    OR:
    15:30-17:10 Scientific session 9: Basic Science: Evolving concepts of IBD pathogenesis
    Massimo Fantini, Rome, Italy
    Britta Siegmund, Berlin, Germany
      15:30-15:50 Pathogenesis of fistulising IBD
    Michael Scharl, Zurich, Switzerland
      15:50-16:00 OP027: SUCNR1 receptor mediates intestinal fibrosis
    J. Cosin-Roger1, 2, D. Ortiz-Masia2, D.C. Macias-Ceja1, L. Gisbert-Ferrandiz2, P. Salvador2, M. Hausmann3, G. Rogler3, S. Calatayud2, M.D. Barrachina2
    1. Fisabio, Hospital Dr Peset, Valencia, Spain
    2. University of Valencia, Valencia, Spain
    3. University of Zurich, Gastroenterology, Zurich, Switzerland
      16:00-16:10 OP028: Single cell RNA sequencing of t-cells in Crohn’s Disease identifies tissue specific drug target
    E. Festen1, R. Weersma1, W.T. Uniken Venema1, M.D. Voskuil1, D. Graham2
    1. University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, Netherlands
    2. The Broad Institute of MIT and Harvard, Cambridge, United States
      16:10-16:30 Stress-induced controllers of intestinal inflammatory reactions Hermona Soreq, Jerusalem, Israel
      16:30-16:40 OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice
    M. Yabal1, A. Wahida1, B. Popper2, K. Steiger3, P. Jost1
    1. Technical University Munich, III. Medizinische Klinik, Munich, Germany
    2. Ludwig-Maximilian University of Munich, Department for Cell Biology, Munich, Germany
    3. Technical University Munich, Institut for Pathologie, Munich, Germany
      16:40-16:50 OP030: Loss of PTPN2 in dendritic cells promotes T cell activation and expression of co-stimulatory molecules
    L. Hering1, C. Gottier1, S. Lang1, B. Becher2, G. Rogler1, M. Scharl1, M. Spalinger1
    1. University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland
    2. University of Zurich, Institute of Experimental Immunologx, Zurich, Switzerland
      16:50-17:10 How the gut speaks to the liver: Novel insights from PSC pathogenesis
    Herbert Tilg, Innsbruck, Austria
    17:20-18:20 Digital Oral Presentations (Sessions 6-10)
    18:35-19:35 Industry sponsored satellite symposia 4a, 4c & 4d

  • Plenary hall

    08:30-10:20 Scientific session 10: Growing up with IBD safely
    Arie Levine, Tel Aviv, Israel
    Murat Toruner, Ankara, Turkey
      08:30-08:50 Safe use of drugs in paediatric and elderly populations
    Gigi Veereman, Brussels, Belgium
    Pieter Hindryckx, Ghent, Belgium
      08:50-09:00 OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s Disease: 12 month data from the PANTS study
    N.A. Kennedy1, G. Heap1, 2, B. Hamilton1, G.J. Walker1, C. Bewshea1, S. Bouri3, J. Goodhand1, PANTS Investigator Consortium, T. Ahmad1
    1. University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom
    2. Abbvie, Chicago, United States
    3. St Mark's Hospital, IBD Unit, London, United Kingdom
      09:00-09:10 OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab
    A. Moens1, 2, K. van Hoeve2, 3, E. Humblet4, J.-F. Rahier5, P. Bossuyt6, S. Dewit7, D. Franchimont8, E. Macken9, J. Nijs10, A. Posen11, A. Van Hootegem12, W. Van Moerkercke13, S. Vermeire1, 2, M. Ferrante1, 2
    1. University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
    2. KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium
    3. University Hospitals Leuven, Department of Paediatric gastroenterology, Leuven, Belgium
    4. Ziekenhuis Oost-Limburg-Campus Sint-Jan, Department of Gastroenterology and Hepatology, Genk, Belgium
    5. CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium
    6. Imeldaziekenhuis, Department of Gastroenterology and Hepatology, Bonheiden, Belgium
    7. Mariaziekenhuis Noord-Limburg, Department of Gastroenterology and Hepatology, Overpelt, Belgium
    8. Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
    9. University Hospital Antwerp, Department of Gastroenterology and Hepatology, Antwerp, Belgium
    10. Sint-Trudo Ziekenhuis, Department of Gastroenterology and Hepatology, Sint-Truiden, Belgium
    11. AZ Vesalius, Department of Gastroenterology and Hepatology, Tongeren, Belgium
    12. AZ Klina, Department of Gastroenterology and Hepatology, Brasschaat, Belgium
    13. AZ Groeninge, Department of Gastroenterology and Hepatology, Kortrijk, Belgium
      09:10-09:30 ESPGHAN-ECCO Guidelines: Update on Paediatric UC Treatment
    Dan Turner, Jerusalem, Israel
    Richard Russell, Glasgow, United Kingdom
      09:30-09:40 OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with Ulcerative Colitis – results from the tofacitinib Ulcerative Colitis clinical programme
    B.E. Sands1, P.R. Taub2, B.G. Feagan3, A. Armuzzi4, G.S. Friedman5, M. Moscariello5, N. Lawendy5, R.D. Pedersen5, G. Chan5, C.I. Nduaka5, D. Quirk5, L. Salese5, C. Su5
    1. Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States
    2. UC San Diego School of Medicine, Division of Cardiovascular Medicine, La Jolla, CA, United States
    3. Western University, Robarts Clinical Trials, London, ON, Canada
    4. Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy
    5. Pfizer Inc, Collegeville, PA, United States
      09:40-09:50 OP034: The initiation of thiopurines in elderly patients with Inflammatory Bowel Disease is associated with an increased risk of adverse effects: A case-control study of the eneida registry
    M. Calafat1, 2, M. Mañosa3, 4, F. Cañete3, J. Panés4, 5, V. García Sánchez4, 6, M. Calvo7, F. Rodríguez-Moranta8, C. Taxonera9, P. Nos4, 10, A. López Sanromán11, M.D. Martín Arranz12, M. Mínguez13, J.P. Gisbert4, 14, S. García-López15, R. de Francisco16, F. Gomollón4, 17, X. Calvet4, 18, E. Garcia-Planella19, M. Rivero20, J. Martínez-Cadilla21, F. Argüelles22, L. Arias García23, M. Cimavilla24, Y. Zabana4, 25, L. Márquez26, A. Gutiérrez4, 27, G. Alcaín28, P. Martínez Montiel29, J. Lázaro30, D. Busquets31, M.F. García Sepulcre32, C. Verdejo33, F. Bermejo34, M. Mora35, D. Monfort36, P. Romero37, B. Velayos38, C. Rodríguez39, A. Rodríguez40, O. Merino41, A. Rodríguez-Pescador42, L. Bujanda4, 43, Y. Ber44, M. Vela45, O. Roncero46, J.M. Huguet47, O. García-Bosch48, M. Barreiro-de-Acosta49, R.E. Madrigal50, L. Ramos51, M. Van Domselaar52, P. Almela53, J. Llaó54, A.J. Lucendo4, 55, C. Muñoz Vilafranca56, À. Abad57, M. Charro58, J. Legido59, J. Riera1, S. Khorrami60, E. Sesé61, A.M. Trapero62, E. Domènech3, 4
    1. Hospital Son Llàtzer, Palma, Spain
    2. Universitat Autònoma de Barcelona, Barcelona, Spain
    3. Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    4. CIBERehd Instituto de Salud Carlos III, Madrid, Spain
    5. Hospital Clínic, Barcelona, Spain
    6. Hospital Reina Sofia, Córdoba, Spain
    7. Hospital Puerta de Hierro, Majadahonda, Spain
    8. Hospital Bellvitge, L’Hospitalet de Llobregat, Spain
    9. Hospital Clínico San Carlos, Madrid, Spain
    10. Hospital La Fe, Valencia, Spain
    11. Hospital Ramón y Cajal, Madrid, Spain
    12. Hospital La Paz, Madrid, Spain
    13. Hospital Clínico de Valencia, Valencia, Spain
    14. Hospital La Princesa, Madrid, Spain
    15. Hospital Universitario Miguel Servet, Zaragoza, Spain
    16. Hospital Universitario Central de Asturias, Oviedo, Spain
    17. Hospital Clínico Lozano Blesa, Zaragoza, Spain
    18. Hospital Parc Taulí, Sabadell, Spain
    19. Hospital Santa Creu i Sant Pau, Barcelona, Spain
    20. Hospital Universitario Marqués de Valdecilla, Santander, Spain
    21. Complexo Hospital Universitario de Vigo, Vigo, Spain
    22. Hospital Virgen de la Macarena, Sevilla, Spain
    23. Hospital Universitario Burgos, Burgos, Spain
    24. Hospital Río Hortega, Valladolid, Spain
    25. Hospital Mutua de Terrassa, Terrassa, Spain
    26. Hospital del mar, Barcelona, Spain
    27. Hospital General Universitario de Alicante, Alicante, Spain
    28. Hospital Clínico de Málaga, Málaga, Spain
    29. Hospital 12 de octubre, Madrid, Spain
    30. Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
    31. Hospital Dr Josep Trueta, Girona, Spain
    32. Hospital General Universitario de Elche, Elche, Spain
    33. Hospital General de Ciudad Real, Ciudad Real, Spain
    34. Hospital Universitario Fuenlabrada, Fuenlabrada, Spain
    35. Hospital Manises, Manises, Spain
    36. Consorci sanitari de Terrassa, Terrassa, Spain
    37. Hospital Santa Lucía, Cartagena, Spain
    38. Hospital Clínico Universitario Valladolid, Valladolid, Spain
    39. CH de Navarra, Pamplona, Spain
    40. Hospital Universitario de Salamanca, Salamanca, Spain
    41. Hospital de Cruces, Barakaldo, Spain
    42. Hospital Galdakao, Galdakao, Spain
    43. Instituto Biodonostia UPV/EHU, (Donostia, Spain
    44. Hospital San Jorge, Huesca, Spain
    45. Hospital Nuestra Sra Candelaria, Sta Cruz Tenerife, Spain
    46. Hospital Mancha Centro, Alcazar de San Juan, Spain
    47. Hospital General Universitario Valencia, Valencia, Spain
    48. Hospital Moisès Broggi, St Joan Despí, Spain
    49. CH Santiago, Santiago de Compostela, Spain
    50. CH de Palencia, Palencia, Spain
    51. Hospital Universitario de Canarias, La Laguna, Spain
    52. Hospital Torrejón, Torrejón, Spain
    53. HG de Castelló, Castelló, Spain
    54. Hospital Sant Joan de Déu-Althaia, Manresa, Spain
    55. Hospital General de Tomelloso, Tomelloso, Spain
    56. Hospital Basurto, Bilbao, Spain
    57. Hospital Viladecans, Viladecans, Spain
    58. Hospital Royo Vilanova, Zaragoza, Spain
    59. Hospital General, Segovia, Spain
    60. Hospital Son Espases, Palma, Spain
    61. Hospital Arnau de Vilanova, Lleida, Spain
    62. Complejo Hospitalario de Jaén, Jaén, Spain
      09:50-10:00 OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations
    G. Walker1, 2, J. Harrison3, M. Voskuil4, G. Heap1, 2, N. Heerasing1, 2, P. Hendy1, 2, J. Koskela5, 6, M. Daly5, 6, H. Sokol7, D. McGovern8, R. Weersma4, C. Bewshea1, M. Weedon3, J. Goodhand1, 2, N. Kennedy1, 2, T. Ahmad1, 2, IBD Pharmacogenetics Study Group
    1. University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom
    2. Royal Devon & Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom
    3. University of Exeter, Exeter Medical School Bioinformatics Team, Exeter, United Kingdom
    4. University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands
    5. The Broad Institute of MIT and Harvard, Cambridge, United States
    6. Massachusetts General Hospital, Analytical and Translational Genetics Unit, Boston, United States
    7. Hôpital Saint-Antoine, Service de Gastroentérologie et Nutrition, Paris, France
    8. Cedars-Sinai Medical Center, Inflammatory Bowel Disease Center, Division of Gastroenterology, Los Angeles, United States
      10:00-10:20 Monitoring and improving safety of new agents
    Miguel Regueiro, Pittsburgh, United States
    10:20-10:50 Coffee Break
    10:50-12:20 Scientific session 11: Colorectal Cancer in IBD
    Jessica de Bruyn, Amsterdam, The Netherlands
    Mircea Diculescu, Bucharest, Romania
      10:50-11:10 Molecular basis of dysplasia in IBD - clues for cancer prevention therapies?
    Laurence Egan, Galway, Ireland
      11:10-11:20 OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with Inflammatory Bowel Disease: A nationwide cohort study
    M. de Jong1, S. van Tilburg1, 2, L. Nissen2, W. Kievit1, I. Nagtegaal3, F. Hoentjen1, L. Derikx1, 2
    1. Radboud University Nijmegen Medical Centre, Gastroenterology and Hepatology, Nijmegen, Netherlands
    2. Jeroen Bosch Hospital, Gastroenterology and hepatology, S Hertogenbosch, Netherlands
    3. Radboud University Nijmegen Medical Centre, Pathology, Nijmegen, Netherlands
      11:20-11:40 Serrated lesions in IBD
    Roger Feakins, London, United Kingdom
    Maria Pellise, Barcelona, Spain
      11:40-11:50 OP037: Risk of cancer in Inflammatory Bowel Disease patients is associated with age and recent use of immunomodulators, while biologics and aminosalicylates are protective factors - a cross-sectional and follow-up analysis of the Swiss IBD cohort Study
    T. Greuter1, S. Scharl1, C. Barthel1, J.-B. Rossel2, L. Biedermann1, B. Misselwitz1, S. Vavricka1, G. Rogler1, M. Scharl1, on behalf of the Swiss IBD Cohort Study Group
    1. University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland
    2. University Hospital Lausanne - CHUV, Institute of Social and Preventive Medicine, Lausanne, Switzerland
      11:50-12:00 OP038: Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammation
    S. Zundler1, E. Becker1, M. Spocinska1, L. Parga-Vidal2, R. Stark2, R. Atreya1, T. Rath1, M. Leppkes1, C. Neufert1, I. Atreya1, K. van Gisbergen2, M.F. Neurath1
    1. University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany
    2. Academic Medical Center, Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands
      12:00-12:20 Endoscopic resection of dysplasia - mucosal and submucosal resection
    Raf Bisschops, Leuven, Belgium
    12:20-12:50 Scientific session 12: ECCO Lecture
    Silvio Danese, Milan, Italy
    Julián Panés, Barcelona, Spain
      12:20-12:50 Is translation the way to treatment personalisation?
    Yehuda Chowers, Haifa, Israel
    12:50-12:55 Awards and closing remarks
    Julián Panés, Barcelona, Spain
    12:55 The ECCO Film 2018